NCT07434843招募中2 期
PEMIGIST: Phase 2 Study of Pemigatinib (INCB054828) in the Treatment of Patients With Advanced SDH-deficient Gastrointestinal Stromal Tumor (GIST)
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 24
- 试验地点
- 1
- 主要终点
- Objective radiographic response rate
研究概览
简要总结
The purpose of this study is to determine how effective the drug pemigatinib is as a treatment option for advanced succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumors(GIST). This study will also assess the side effects associated with pemigatinib and evaluate its tolerability.
The name of the study drug involved in this study is:
• Pemigatinib (INCB054828)
详细描述
This is a single-arm, open-label Phase 2 trial evaluating the clinical efficacy of pemigatinib (INCB054828) in patients with advanced succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumors.
The U.S. Food and Drug Administration (FDA) has not approved pemigatinib for advanced succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumors but it has been approved for other uses.
The research study procedures include screening for eligibility, study treatment in-clinic visits, physical exam, routine blood tests, pregnancy test, Electrocardiogram (ECG),Imaging Scans, Tumor sample, Data and biological specimen collection.
Eligible participants will receive oral pemigatinib (INCB054828) continuously in 21-day cycles until disease progression or unacceptable toxicity. Follow up will begin 30 days after treatment stops.
It is expected that about 24 people will take part in this research study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participant must have histologically confirmed SDH-deficient GIST. Participants must have locally advanced or metastatic disease that is not amenable to surgery.
- •Participants must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as ≥20 mm (≥2 cm) by chest x-ray or as ≥10 mm (≥1 cm) with CT scan, MRI, or calipers by clinical exam. See Section 12 (Measurement of Effect) for the evaluation of measurable disease.
- •Participants must have radiographically documented progressive disease prior to study enrollment as per investigator assessment.
- •Age ≥18 years
- •ECOG performance status ≤2
- •Participants must have adequate organ and marrow function as defined below:
- •Hemoglobin > 8 g/dL. Patients with a hemoglobin of 7.5-8.0 g/dL may be eligible if the value is chronic, there is no clinical evidence of active bleeding, and eligibility is confirmed upon review and approval of the Sponsor-Investigator
- •Absolute neutrophil count ≥1,000/mcL
- •platelets ≥100,000/mcL
- •total bilirubin ≤1.5 × institutional upper limit of normal (ULN)
- •AST(SGOT)/ALT(SGPT) ≤3.0 × institutional ULN (unless liver metastases are present in which case it must be ≤ 5 × ULN)
- •glomerular filtration rate (GFR) ≥60 mL/min/1.73 m2 (using the CDK-EPI formula see Appendix B)
- •Human immunodeficiency virus (HIV)-infected participants on effective non-CYP3A4 interacting (see Section 3.2.3) anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial.
- •For participants with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated.
- •Participants with a history of hepatitis C virus (HCV) infection must have been treated and cured. For participants with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.
- •Participants with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression.
- •Participants must be disease-free of prior invasive malignancies for > 5 years with the exception of curatively-treated basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix. NOTE: If there is a history of prior malignancy, participants must not be receiving other specific treatment for that cancer.
- •Participants should have completed prior treatment for their cancer: chemotherapy or radiotherapy must have been completed for greater than 2 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study.
- •Participants should have recovered from adverse events due to prior anti-cancer therapy (i.e.,have residual toxicities > Grade 1) with the exception of alopecia.
- •Participants with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, participants should be class 2B or better.
- •Participants must have a QTc interval length of below 450 msec. QTc will be calculated via the Fridericia's formula.
- •Participant is willing to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up.
- •Participant must be able to swallow and maintain pills.
- •Women of childbearing potential must have a negative urine or serum pregnancy test within 28 days of initial dose of pemigatinib (INCB054828), and again within 7 days prior to treatment on day
- •If screening occurs within 7 days of day 1, only one regnancy test is required.
- •Ability to understand and the willingness to sign a written informed consent document. Participants with impaired decision-making capacity (IDMC) who have a legally authorized representative (LAR) and/or family member available will also be eligible.
排除标准
- •Participants who are receiving any other investigational agents.
- •History of allergic reactions attributed to compounds of similar chemical or biologic composition to pemigatinib (INCB054828).
- •Concomitant administration with sensitive substrates/narrow therapeutic index drugs of CYP3A4, P-gp BCRP, MATE1, and MATE2K, and strong inhibitors and inducers of CYP3A4 should be avoided. Use caution with strong inhibitors and inducers of P-gp. Because the lists of these agents are constantly changing, it is important to regularly consult a frequently-updated medical reference. As part of the enrollment/informed consent procedures, the participant will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the participant is considering a new over-the-counter medicine or herbal product. (See Appendix C Participant Drug Information Handout and Wallet Card).
- •Participants with uncontrolled intercurrent illness.
- •Participants with psychiatric illness/social situations that would limit compliance with study requirements.
- •Women of childbearing potential unwilling or unable to perform contraception from screening until 4 months after completion of pemigatinib administration
- •Men unwilling or unable to perform contraception from screening to until 4 months after completion of pemigatinib administration.
- •Participants previously treated with a FGFR inhibitor.
- •History of hypovitaminosis D requiring supraphysiologic doses (e.g., 50,000 UI/weekly or above). Vitamin D supplements are allowed.
- •Participants with calcium and phosphate levels exceeding the upper limit of normal (ULN) despite medical intervention within 2 weeks prior to the first dose of pemigatinib.
- •Current evidence of corneal or retinal abnormalities that may increase eye toxicity, including but not limited to:
- •Currently suffering from central serous retinopathy (CSR) or retinal vein occlusion (RVO), or with relevant history
- •Active wet age-related macular degeneration (wAMD)
- •Diabetic retinopathy with macular edema
- •Uncontrollable glaucoma
- •Keratopathy, such as keratitis, keratoconjunctivitis, keratopathy, corneal abrasion, inflammation or ulceration
- •Treatment with any potent CYP3A4 inhibitors or inducers or moderate CYP3A4 inducers within 14 days or 5 half-lives (whichever is longer) before the first dose of study drug.
- •Participants with a history of soft tissue calcifications on imaging that are associated with documented abnormalities in calcium or phosphate levels except for soft tissue calcification due to aging, previous injury or other disease
研究组 & 干预措施
PEMIGATINIB
Experimental
Pemigatinib will be taken orally 1x daily on Days 1-14, not taken days 15-21 of each 21-day study cycle (2 weeks on, 1 week off).
Cycles will continue until disease progression, unacceptable toxicity, or other protocol-defined criteria
干预措施: Pemigatinib (Drug)
结局指标
主要结局
Objective radiographic response rate
时间窗: From first dose of pemigatinib until the date of objective response per RECIST 1.1 through study completion, an average of 1 year
The objective response rate is defined as the rate of participants with a complete response or partial response, calculated using RECIST 1.1.
次要结局
- Progression-free survival (PFS)(Participants alive without disease progression are censored at the earliest date of last disease evaluation or off treatment date] average of 2yrs.)
- Incidence of Grade 3 or Higher Treatment-Related Toxicity(From first dose of pemigatinib through 30 days after last dose of pemigatinib (approximately up to 36 months total on study time).)
研究者
Suzanne George, MD
Principal Investigator
Dana-Farber Cancer Institute
研究点 (1)
Loading locations...
相似试验
已完成
2 期
PEARLDIFER - A Phase II study of pemigatinib after curative local therapy in locally advanced intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions/rearrangements2024-512018-16-00Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH20
招募中
3 期
A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First-Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement (FIGHT-302)Cholangiocarcinoma2024-513513-12-00Incyte Corp.110
招募中
2 期
KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting (SynerGIST-1st Line)GISTNCT07406633Kumquat Biosciences Inc.46
招募中
1 期
Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After TreatmentNCT07463807National Cancer Institute (NCI)162
招募中
3 期
Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPCNCT07459296First Affiliated Hospital of Guangxi Medical University266